Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | NMT2 | O60551 | 3/20 | 0.46 |
| ▸ | NMT1 | P30419 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12680258 | 1.00 | TLR2 (0.56) | TLR2GLP1RSIRT6SIRT1NMT2 | |
| SCHEMBL13347258 | 0.94 | TLR2 (0.49) | TLR2GLP1RSIRT6SIRT1NMT2 | |
| SCHEMBL14903000 | 0.91 | GLP1R (0.49) | TLR2GLP1RSIRT6SIRT1SIRT5 | |
| SCHEMBL13371966 | 0.89 | GLP1R (0.48) | TLR2GLP1RSIRT6SIRT1NMT2 | |
| SCHEMBL16327810 | 0.89 | TLR2 (0.57) | TLR2GLP1RSIRT6SIRT1NMT2 | |
| SCHEMBL45887 | 0.86 | GLP1R (0.57) | TLR2GLP1R | |
| SCHEMBL30094802 | 0.85 | GLP1R (0.59) | TLR2GLP1RSIRT6SIRT1NMT2 | |
| SCHEMBL13347272 | 0.84 | GLP1R (0.48) | TLR2GLP1RSIRT6SIRT1NMT2 | |
| SCHEMBL12680289 | 0.84 | ALB (0.48) | CHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL25454957 | 0.83 | GLP1R (0.46) | TLR2GLP1RNMT2NMT1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100111865-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| US-20100111865-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111865-A1 | CONTRAST AGENTS | CSGALNACT1, HPSE, SERPINC1 | TLR2 1504/4885GLP1R 809/4885SIRT6 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.